Mirabegron for the treatment of retinal diseases
US11717513B2 · kind B2 · utility
0Cited by
9References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 17, 2016 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | Nov 24, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.